Browse EX-10 agreements

PLACEMENT AGENCY AGREEMENT

Dawson James Securities, Inc.
2700 N Military Trail, Suite 100
Boca Raton, FL 33431

September 18, 2026

Ladies and Gentlemen:

This letter (this “Agreement”) constitutes the agreement between Alaunos Therapeutics, Inc., a Delaware corporation (the “Company”), and Dawson James Securities, Inc. (“Dawson”) pursuant to which Dawson shall serve as the placement agent (the “Placement Agent”) (the “Services”), for the Company, on a reasonable “best efforts” basis, in connection with the proposed offer and placement (the “Offering”) by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson’s obligations hereunder are on a reasonable “best efforts” basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities. The terms of the Offering and the Securities shall be mutually agreed upon by the Company

…

Alaunos Therapeutics, Inc.

September 18, 2026

Alaunos Therapeutics, Inc.

501 E. Las Olas Blvd., Suite 300
Fort Lauderdale, FL 33301
Telephone: [***]
Attention: Holger Weis, Chief Executive Officer
E-mail: [***]

Re: Alaunos Therapeutics, Inc. - Lock-Up Agreement

Dear Sirs:

This Lock-Up Agreement is being delivered to you in connection with the Placement Agency Agreement (the “Placement Agency Agreement”), dated as of September 18, 2026, by and among Alaunos Therapeutics, Inc. (the “Company”) and Dawson James Securities, Inc. (the “Placement Agent”), with respect to the issuance of the Company’s shares of Common Stock, par value $0.001 per share (the “Common Stock”), and pre-funded warrants (the “Warrants”) to purchase Common Stock. Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Placement Agency Agreement or the Securities Purchase Agreement, dated as of September 18, 2026, by and among the Company and the purchasers named therein (the “Securities Purchase Agreement”).

…

To:					CoreWeave, Inc.290 W Mt. Pleasant Ave., Suite 4100Livingston, NJ 07039
From:					[Dealer Name and Address]
Re:					Base Capped Call Transaction
Date:					September 17, 2026

Dear Ladies and Gentlemen:

…

To:					CoreWeave, Inc.290 W Mt. Pleasant Ave., Suite 4100Livingston, NJ 07039
From:					[Dealer Name and Address]
Re:					Additional Capped Call Transaction
Date:					September 18, 2026

Dear Ladies and Gentlemen:

…

Associated Banc-Corp

September 21, 2026

VIA EMAIL ONLY

Mr. Randall J. Erickson

111 East Kilbourn Avenue, Suite 200

Milwaukee, WI 53202

Randall.Erickson@associatedbank.com

	Re:	Employment Transition – Letter Agreement

Dear Randy:

The purpose of this letter agreement (the “Agreement”) is to memorialize the terms of the employment transition that you will soon make from Executive Vice President, General Counsel and Corporate Secretary, to Attorney-Advisor. If you agree to these terms, please sign and date where indicated and return a copy to me.

As you know, you are currently Executive Vice President, General Counsel and Corporate Secretary, and hold certain offices with Associated Banc-Corp (“ASB”) and its subsidiaries.

As you also know, we agree that you will transition your employment to Attorney-Advisor, upon the terms and conditions set forth herein.

…

**TERMINATION **

**OF THE **

LICENSE AND DISTRIBUTION AGREEMENT

This Termination of the License and Distribution Agreement ("Termination Agreement") is made and entered into as of June 23, 2026 (the "Effective Date"), by and between Aytu BioPharma, Inc., with a business address of 7900 E Union Avenue, Suite 920, Denver, CO 80237, (“Aytu”), and Lannett Company, Inc., 1150 Northbrook Drive, Suite 155, Trevose, PA 19053, together with its Affiliates (“Lannett”). Aytu and Lannett are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

RECITALS

WHEREAS, Lannett and Aytu are parties to the License and Distribution Agreement, effective as of May 11, 2022, and amended on July 6, 2023 and July 17, 2025 (“Metadate Agreement”) whereby Lannett transferred its New Drug Application 021259 (the “NDA”) for methylphenidate hydrochloride extended-release capsules, FDA-approved under the brand name Metadate CD®, (the “Product”) to Aytu, as well as licensed the Metadate CD trademark® to Aytu;

…

** **

Exhibit 10.1

** **

INVESTMENT MANAGEMENT TRUST AGREEMENT

This Investment Management Trust Agreement (this “Agreement”) is made effective as of September ___, 2026 by and between AEI CapForce II Investment Corp, a Cayman Islands exempted company (the “Company”), and Efficiency INC., a Delaware corporation (the “Trustee”).

** **

WHEREAS, the Company’s registration statement on Form S-1, File No. 333-281101 (the “Registration Statement”) and prospectus (the “Prospectus”) for the initial public offering (the “Offering”) of the Company’s units (the “Units”), each of which consists of one Class A ordinary share, par value $0.0001 per share (the “Ordinary Shares”), one redeemable warrant to purchase one Share at $11.50 per share and one right to receive one-third (1/3) of one Class A ordinary share, has been declared effective as of the date hereof by the U.S. Securities and Exchange Commission; and

** **

…

* *

September[_], 2026

AEI CapForce II Investment Corp

Duplex Penthouse, Unit A-33-6

Level 33, Tower A

UOA Bangsar Tower, No. 5

Bangsar Utama 1 Road

59000 Kuala Lumpur, Malaysia

	Re:	Initial Public Offering

Ladies and Gentlemen:

This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between AEI CapForce II Investment Corp, a Cayman Islands exempted company (the “Company”), and R. F. Lafferty & Co., Inc., as representative of the several underwriters (the “Underwriter”), relating to an underwritten initial public offering (the “Public Offering”), of up to 11,500,000 of the Company’s units (including up to 1,500,000 units that may be purchased to cover over-allotments, if any) (the “Units”), each comprised of one share of the Company’s Class A ordinary shares, par value $0.0001 per share (the “Class A ordinary shares”), and one one

…

____________, 2026

AEI CapForce II Investment Corp

Duplex Penthouse, Unit A-33A-6

Level 33, Tower A, UOA Bangsar Tower

No. 5, Bangsar Utama 1 Road,

59000 Kuala Lumpur, Malaysia

	Re:	Form of Placement Unit Purchase Agreement

Ladies and Gentlemen:

AEI CapForce II Investment Corp (the “Company”), a blank check company formed for the purpose of acquiring one or more businesses or entities (a “Business Combination”), intends to register its securities under the Securities Act of 1933, as amended (“Securities Act”), in connection with its initial public offering (“IPO”), pursuant to a registration statement on Form S-1 (“Registration Statement”).

…

EXECUTION COPY

The FOURTH AMENDMENT

TO AMENDED AND RESTATED SENIOR SECURED REVOLVING CREDIT AGREEMENT

THIS FOURTH AMENDMENT TO AMENDED AND RESTATED SENIOR SECURED REVOLVING CREDIT AGREEMENT, dated as of September 16, 2026 (this “Amendment”), to the Existing Credit Agreement (capitalized terms used herein and not otherwise defined shall have the meanings given to such terms in Article I) is among BLUE OWL CREDIT INCOME CORP. (f/k/a OWL ROCK CORE INCOME CORP.), a Maryland corporation (the “Borrower”), solely with respect to Section 5.9 herein, the SUBSIDIARY GUARANTORS party hereto, the LENDERS party hereto and SUMITOMO MITSUI BANKING CORPORATION, as Administrative Agent (the “Administrative Agent”) and, solely with respect to Section 5.11 herein, as Collateral Agent (in such capacity, the “Collateral Agent”).

W I T N E S S E T H:

…

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of September 16, 2026, between SCWorx Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below), and/or Rule 506 of Regulation D promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

** **

ARTICLE I.
DEFINITIONS

…

[NAME]

Re:    Retention Letter

Dear [NAME]:

I am writing on behalf of the Board of Directors (the “Board”) of Adobe Inc. (“Adobe,” “we,” “us,” or “our”) — and speaking personally as well — to express our genuine appreciation for your continued leadership and dedication during this important period of transition. As you know, we are currently conducting a search for our next Chief Executive Officer, and the Board and I recognize that this process creates a degree of uncertainty — particularly for those, like you, whose steady hand and day-to-day contributions are so critical to our continued success during the search.

…